Chronic anxiety disorders produce prolonged distress and functional impairment across personal, occupational, and social domains, creating a substantial public health burden recognized by the World Health Organization. Constellations of generalized anxiety disorder, panic disorder, social anxiety disorder, and other persistent anxiety conditions often coexist with depressive or physical health comorbidities, complicating diagnosis and long-term management. Persistent symptoms are shaped by biological vulnerability, learned avoidance and safety behaviors, and environmental stressors, with cultural and territorial variations in symptom expression and help-seeking patterns that influence access to effective care.
Core psychological treatments
Cognitive behavioral therapy emerges consistently as a primary evidence-based approach. Research led by David H. Barlow Boston University describes structured interventions that target maladaptive thoughts and avoidance through cognitive restructuring and behavioral experiments, and meta-analyses by Stefan G. Hofmann Boston University document robust symptom reduction across anxiety diagnoses. Exposure-based techniques within behavioral therapy are especially effective for specific phobias and panic disorder, and group formats or guided self-help deliverable in community settings expand reach while respecting cultural contexts. Cochrane Collaboration systematic reviews corroborate benefits of psychotherapy compared with minimal interventions.
Pharmacological management
Practice guidelines from the American Psychiatric Association and recommendations from the National Institute for Health and Care Excellence support selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors as first-line pharmacotherapy for many chronic anxiety disorders. These agents, including commonly prescribed compounds such as sertraline and venlafaxine, reduce physiological and cognitive symptoms and are often recommended when symptom severity or functional impairment is substantial. Short-term use of benzodiazepines can provide rapid relief but carries dependence and cognitive risk, leading specialist guidance to favor limited-duration use and careful monitoring. Cochrane Collaboration reviews provide pooled evidence for medication efficacy while indicating the need for individualized risk–benefit assessment.
Integrated and contextual strategies
Combining psychotherapy and pharmacotherapy frequently produces superior outcomes for persistent or severe presentations, and stepped-care models supported by the World Health Organization mhGAP framework enhance scalability in low-resource settings. Adjunctive approaches such as mindfulness-based interventions, lifestyle modification, and community-based psychosocial support address cultural and territorial determinants of chronic anxiety and mitigate disability. Treatment selection benefits from multidisciplinary coordination, attention to comorbid medical conditions, and adaptation to local health systems to ensure sustainable, evidence-informed management.
